SkinStylus Receives FDA Clearance for Periorbital Wrinkles Across All Skin Types

What happened

The U.S. Food and Drug Administration cleared the SkinStylus SteriLock MicroSystem for the improvement of periorbital wrinkles in adults aged 22 and older across all Fitzpatrick skin types I-VI. This expands the device's FDA-cleared indications, which already included improving facial acne scars (in Fitzpatrick skin types I-III) and abdominal surgical or traumatic hypertrophic scars. The clinical data supporting the new indication was presented at the 2026 SCALE Annual Meeting. According to the principal investigator in the clinical study, Dr. Glynis Ablon, the device demonstrated statistically and clinically meaningful improvements in periorbital wrinkles across all skin types, with patients reporting greater comfort compared to other microneedling systems.

Why it matters

The expanded clearance strengthens SkinHealth Systems' competitive position in the rapidly growing microneedling market. Consumer spending on microneedling in U.S. medical aesthetic practices reached approximately $330 million in 2025, growing 33% year-over-year. Periorbital wrinkles remain among the most common aesthetic concerns worldwide, and the new indication allows SkinStylus to address this demand across all skin types. The company reported that approximately one in five Hydrafacial treatment consumers also received microneedling last year, reflecting growing demand for combination treatment protocols. Looking ahead, 90 percent of Hydrafacial consumers expressed interest in combining microneedling with Hydrafacial treatments to maximize results, suggesting strong potential for cross-selling within SkinHealth Systems' product ecosystem.

Bigger picture

Microneedling is experiencing significant momentum within the broader medical aesthetics industry. Categorized as a minimally invasive procedure using fine needles to create controlled micro-injuries that support the skin's natural renewal process, microneedling has gained mainstream acceptance partly through celebrity endorsements from figures like Jennifer Aniston and Kim Kardashian. Industry experts attribute the treatment's lasting appeal to its ability to stimulate collagen production and deliver visible results with minimal downtime, typically requiring about 30 minutes per session. The strong growth in consumer spending reflects an increasing preference for clinically driven, skin-quality treatments over more invasive procedures. SkinStylus now holds multiple FDA clearances as a Class II Medical Device, positioning it uniquely in a competitive landscape that includes devices like Collagen PIN.

What to watch

Monitor adoption rates of SkinStylus treatments among aesthetic providers, particularly those already offering Hydrafacial services. The pairing of Hydrafacial with microneedling represents a significant commercial opportunity given the high expressed interest from consumers. Watch for updates on clinical study results and additional indications, as expanding FDA clearances could further differentiate SkinStylus in the microneedling category. Track quarterly revenue contribution from the SkinStylus product line and commentary on provider uptake. Also observe whether competitors pursue similar multi-indication strategies or broader skin type clearances.